These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 7689923)

  • 1. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
    Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
    Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucin 1 antigens in the serum and bronchial lavage fluid of patients with lung cancer.
    Willsher PC; Xing PX; Clarke CP; Ho DW; McKenzie IF
    Cancer; 1993 Nov; 72(10):2936-42. PubMed ID: 8221560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
    Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen: clinical and historical aspects.
    Martin EW; Kibbey WE; DiVecchia L; Anderson G; Catalano P; Minton JP
    Cancer; 1976 Jan; 37(1):62-81. PubMed ID: 1247968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MSA as a serum marker in breast cancer: a comparison with CEA.
    Stacker SA; Sacks NP; Golder J; Tjandra JJ; Thompson CH; Smithyman A; McKenzie IF
    Br J Cancer; 1988 Mar; 57(3):298-303. PubMed ID: 3355770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
    Vandenberg TA
    Clin Biochem; 1993 Dec; 26(6):429-30. PubMed ID: 7510220
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
    Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
    Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of carcinoembryonic antigen and a tumor-extracted carcinoembryonic antigen-related antigen in cancer patients.
    Shively JE; Spayth V; Chang FF; Metter GE; Klein L; Presant CA; Todd CW
    Cancer Res; 1982 Jun; 42(6):2506-13. PubMed ID: 7074626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mammary serum antigen (MSA) with beta 2-microglobulin (beta 2M) and carcinoembryonic antigen (CEA) assays in patients with breast cancer.
    Tjandra JJ; McLaughlin PJ; Russell IS; Collins JP; McKenzie IF
    Eur J Cancer Clin Oncol; 1988 Oct; 24(10):1633-40. PubMed ID: 3061824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of cancer procoagulant as an early detection tumor marker.
    Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG
    Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new biomarker in monitoring breast cancer: CA 549.
    Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
    J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.